idea-005 · human · wrapped
Read this before anything else on the page. A low count here is usually a
statement about this repo's tooling rather than about the idea — a
unconfirmed reimbursement claim most often means the CMS cache file
is absent and nothing was searched, which is not evidence that a code
does not exist.
The packet a human reads. See docs/wrap-spec.md. This section says nothing about whether the idea is good — it says the file is finished enough to be read, and names what to do next. Filling it in advances no candidate and approves nothing.
The one-paragraph version. A sleep-apnea test a child can do at home instead of spending a night wired up in a hospital sleep lab. Children with obstructive sleep apnea — usually caused by enlarged tonsils and adenoids — are diagnosed today by an overnight in-laboratory study, which is scarce, expensive, and often months away. This is a portable recorder a parent fits at bedtime: sensors for airflow at the nose, bands around the chest and abdomen to measure breathing effort, and a finger probe for blood oxygen, with scoring software tuned to children's thresholds rather than adults'. It deliberately leaves out the brainwave sensors a lab study uses, which is what makes it simple enough to use at home — and, as this packet shows, is also the core of the objection to it.
What would have to be true, quoted from each deck's load-bearing condition:
Cheapest next test: Read three named commercial medical policies and two state Medicaid policies for home sleep testing, specifically for how the under-18 exclusion is worded — as an age restriction or as a device-clearance restriction. The Scores table isolates this distinction as the conditional the whole reimbursement factor turns on, and the file records no primary source behind the exclusion claim at all. Five documents, read by hand, before any part of the mid-single-digit-million validation study is commissioned. Selected from the Reimbursement row's gap analysis; this is a selection from it, not a new judgement, and not a view about the idea.
Where the evidence actually stands. 7 of 33 claims verified, 25 unconfirmed, 1 refuted. All 9 factors carry a score in the Stage 2 triage table and all 4 core factors do.
This is the best-evidenced candidate in the portfolio on whether the device could work, and among the least evidenced on whether anyone would pay for it. All seven verified claims are clinical or regulatory; not one is commercial. The payer question its own conditional says decides the business has no primary source behind it at all.
The verified evidence is genuinely mixed and a Stage 6 reader should have both halves.
Against. The AASM's 2017 Position Paper states that home sleep apnea testing is not recommended for diagnosing obstructive sleep apnea in children — and the stated reason is the inability to identify literature on devices that monitor CO2 or detect arousals, which the task force viewed as critical in this population [claim 28: verified]. Arousal detection is what the brainwave channel provides, and omitting it is this product's defining design choice. The 2012 AAP technical report separately found that most diagnostic screening tests in this condition had low sensitivity and specificity [claim 29: verified].
In favour. A 2026 systematic review found that in one of the largest simultaneous HSAT-versus-PSG comparisons, mean AHI was 2.5±3 by home test versus 2.7±2.9 in lab, p>0.05 [claim 30: verified] — close agreement, on an EEG-free modality, at the AHI values where the treatment decision is actually made. Home testing is also demonstrably practical for families: in an Australian cohort of 47 children aged 5-16, acceptable recordings were obtained for every home study attempted, with a 6.6% false-positive and 3% false-negative rate [claim 31: verified]. And the burden of the current pathway is real: a Québec series of 82 consecutive adenotonsillectomy patients recorded a mean referral-to-surgery delay of 15.2±8.6 months [claim 32: verified].
Three cautions on reading those. The favourable feasibility result [claim 31: verified] used home Type-2 polysomnography, a montage that includes EEG — so it does not evidence the EEG-free design this candidate proposes. The same systematic review that supplies the favourable concordance figure also reports that only 3 of 9 included studies used simultaneous testing [claim 30: verified], so that evidence base is three studies deep. And both [claim 31: verified] and [claim 32: verified] are non-US studies carrying jurisdiction: US, describing health systems whose access patterns are not the US market's.
Finally, the file's founding premise was refuted, and this remains the most structurally important fact in it: a cleared home airflow/effort recorder already states verbatim that "both pediatric and adult patients may be tested", from a roster of 38 MNR clearances over 2020-2026 [claim 3: refuted]. The pediatric-permitting pathway is demonstrably walkable, several parties have walked it, and the practice has not moved. That refutation cost the candidate its white-space argument and simultaneously supplied its regulatory identification [claim 26: verified] — a refuted claim that is also the most informative one in the file. What the seven verified claims add is a candidate explanation for the silence: not that clearance was unavailable, but that the professional society does not recommend the modality, for a reason aimed at this device's architecture. FTO is unexamined rather than clear [claim 25: unconfirmed], in a field with 38 clearances, on the rubric's one automatic-kill factor.
One defect in the file worth naming rather than quietly working around: [claim 33: unconfirmed] points at "claim 38" as its revealed-behaviour twin, but this file has 33 claims and the study it describes is [claim 32: verified]. Claims are append-only and positional, so the reference is stale rather than ambiguous. It has been left as recorded — rewriting a claim's text would be editing evidence — and the decks cite [claim 32: verified] directly.
| Intended use | For unattended recording of respiratory airflow, respiratory effort, oxygen saturation, pulse rate, and body position in the home, in children aged 5 through 17 years with clinical suspicion of obstructive sleep apnea and without neuromuscular disease, craniofacial syndrome, Down syndrome, sickle cell disease, obesity hypoventilation, or significant cardiopulmonary disease, for interpretation by a qualified sleep physician. |
|---|---|
| Mechanism | Unattended multi-channel home recorder — nasal pressure and thermistor airflow, thoracoabdominal respiratory effort belts sized for pediatric torsos, pulse oximetry with a pediatric probe, body position — scored against pediatric AASM criteria (obstructive events defined over ~2 breaths, pediatric AHI thresholds) rather than adult criteria |
| Device class | # Two genuinely live routes. Which one applies IS the central; Class II — 510(k) — regulation and product code NOT identified by the Generator. The; route is a 510(k) against a cleared adult home-sleep-apnea-test predicate, with the; pediatric population added by indication. Launch designation, and the cheaper of the; two by roughly an order of magnitude.; De Novo — becomes the live route if FDA declines an adult HSAT predicate for a; pediatric indication on the grounds that pediatric event scoring criteria differ from; adult criteria (different hypopnea definition, different AHI thresholds), i.e. that; substantial equivalence fails on intended population. Carried because the Generator; considers this at least as likely as the 510(k) route. |
| Predicate or analog | Adult HSAT devices identified by name via web search only — ApneaLink Air; (ResMed), WatchPAT (Itamar/ZOLL), Alice NightOne (Philips). The Generator; could not identify any device carrying a pediatric OSA indication, which; is the premise of the candidate and also the reason no true predicate may; exist. |
| Launch jurisdiction | US |
| Target | human |
| Factor | Score | What would settle it |
|---|---|---|
| Regulatory pathway | 2 | classification lookup to identify the HSAT product code(s) and regulation number from the device description (candidate codes must be read out of the lookup, not assumed — none is asserted here); then clearances --product-code <code>…the rest of this gap analysisreading Indications for Use text for an explicit age range, which is the single call that decides whether a pediatric predicate exists. Then510k "ApneaLink", 510k "WatchPAT", 510k "Alice NightOne" for the actual cleared indications of the named analogs; the FDA De Novo listing in data/ for any granted pediatric sleep-test De Novo; ecfr on whatever regulation number the classification lookup returns. Residual after all of these: whether FDA will accept an adult HSAT predicate for a pediatric population given different pediatric hypopnea/AHI scoring criteria is a Pre-Submission question, not a database lookup — no connector can close this fork |
| Reimbursement pathway | 1 | coverage on the HSAT codes, targeting CMS NCD 240.4 (sleep testing for OSA) and the MAC LCD/LCA for sleep testing — reading specifically for whether any age limitation is stated and how it is worded. Then 2-3 named commercial and…the rest of this gap analysisstate-Medicaid sleep-testing medical policies, human-attached (payer policy PDFs are not connector-reachable), read for the exact exclusion language: an age-based exclusion and a clearance-based exclusion have opposite implications for claim 9 and that single sentence decides the factor.payment on the HSAT codes for the actual allowed amount, required before this is a pathway rather than a code — a code that pays below the cost of the study plus scoring is not reimbursement. Claims 1-2 descriptors: no connector, ever — needs a human-attached licensed AMA CPT 2026 source |
| TAM | 2 | C1: procedures on the pediatric PSG codes for whatever Medicare-side signal exists, explicitly logged as a wrong-denominator floor for this age band. The real sources are human-attached and licensed: HCUP KID / NIS for pediatric PSG…the rest of this gap analysisand pediatric tonsillectomy volumes, a commercial claims database (MarketScan/Komodo), and Medicaid T-MSIS/TAF for the payer mix that actually dominates pediatric sleep medicine. C2:payment on the HSAT codes as a reimbursement anchor, plus a human-attached adult HSAT contracted-price benchmark. C3: no source can settle the share assumption; the closest defensible substitute is a human-attached count of AASM-accredited facilities with pediatric beds and published pediatric PSG wait times, which is what would test the "in-lab capacity is the rate limiter" premise underneath it |
| FTO / IP | *(blank — no claim exists)* | No connector call is possible yet — patent <number> requires a number and the file contains none. The prerequisite is a search, not a verification: USPTO Patent Public Search / Google Patents over CPC A61B5/0816 and A61B5/087…the rest of this gap analysis(respiration/airflow measurement), A61B5/4818 (sleep apnea diagnosis), A61B5/1455 (pulse oximetry) and A61B5/113 (respiratory effort); assignees ResMed, Philips/Respironics, Itamar/ZOLL, Nox Medical, SleepImage/MyCardio; restricted to claims live past ~2032. Priority targets are (a) automated event-scoring-algorithm patents, since claim 10 names the pediatric scoring algorithm as the defensible asset, and (b) pediatric-specific sensor/sizing art. Each candidate number then goes throughpatent <number> for status and expiry. Full settlement is a counsel-drafted FTO memo at Stage 7 |
| Moat / defensibility | 2 | (a) The FTO search above run offensively — whether the pediatric scoring algorithm is patentable is the difference between a 2 and a 4. (b) trials on NCT05382754 and NCT03748771 (claim 4) to check **who is already building the…the rest of this gap analysispediatric validation dataset** — if an incumbent is sponsoring one, the moat is erased before it exists; NCT03748771's title names ApneaLink Air, so the sponsor field alone is close to decisive and is nearly free to pull. (c)clearances --product-code <code> over a trailing 5 years for the realized fast-follower rate. (d) For the payer-drafting half: a human-attached named coverage policy that conditions payment on age-specific FDA clearance — one policy with that drafting settles it; no connector reaches policy language |
| Mechanism & clinical risk | 2 | trials NCT03748771 and trials NCT05382754 for design, sample size, comparator and any posted results — the highest information-per-call check in the entire file, since it bears on Factors 5, 6 and 7 at once. Then literature on…the rest of this gap analysispediatric HSAT-versus-PSG concordance (sensitivity/specificity at pediatric AHI thresholds), plus a human read of the AASM pediatric practice parameters and the pediatric scoring rules in the AASM scoring manual (licensed, human-attached) — the device must implement those exact criteria, so they are a specification input as well as evidence. Residual: whether this montage achieves acceptable sensitivity is answered by the validation study itself, not by any lookup, and that should be stated rather than papered over |
| Capital intensity & time-to-revenue | 1 | Not primarily a connector question. trials NCT03748771 / NCT05382754 for realized enrollment counts, site counts and start-to-completion dates — the best available benchmark for the dominant cost line and far better than the…the rest of this gap analysiscurrent estimate. FDA MDUFA performance reports for 510(k) versus De Novo decision times in the relevant product code, and thedata/ De Novo listing for decision timelines of comparable diagnostic De Novos. A human-attached CRO quote for a multi-site pediatric PSG-concurrent study. The Generator should also state the post-clearance coverage-campaign cost and duration as its own claim — it currently sits inside claim 9 as reasoning, so it is costed nowhere |
| Competitive intensity | 2 | clearances --product-code <code> over a trailing 5 years — one call that settles claim 3 and the first half of claim 13 simultaneously, giving both the premise of the whole candidate and the incumbent roster with their cleared age…the rest of this gap analysisranges. Then510k "ApneaLink", 510k "WatchPAT", 510k "Alice NightOne" to confirm the named incumbents hold what the claim says; recalls --product-code <code> for realized safety signal and incumbent stumbles. trials on the two NCTs for the sponsor field — an incumbent already running a pediatric validation study is the single most decisive competitive fact available and is one cheap call away. Funding and launch activity needs a human-attached licensed source (PitchBook/Crunchbase); no connector covers it. The incumbent-priorities half is a permanent assumption |
| Strategic fit & portfolio balance | 3 | No connector and no external database. Requires a human-authored portfolio thesis document in the repo (current holdings, capital constraints, target mix of hero bets versus cash-generative spokes, therapeutic-area focus) before any Scorer…the rest of this gap analysiscan score this row non-arbitrarily. Until that exists the factor is unscoreable in the same way Factor 1 would be unscoreable withoutintended_use:, and no Verifier pass can produce a verified claim about a strategy nobody has written down |
All six wrap criteria are met.
Domain dossier: pediatric-obstructive-sleep-apnea-testing
Source file: knowledge-base/candidates/idea-005.md
Nothing on this page is a recommendation. Shortlist review, legal and clinical sign-off and capital allocation are human-only decisions, and no agent in this repo may make or simulate one. This is a compilation of what the candidate file says.